110 related articles for article (PubMed ID: 10974631)
1. CYP2D6 gene polymorphism in caucasian smokers: lung cancer susceptibility and phenotype-genotype relationships.
Laforest L; Wikman H; Benhamou S; Saarikoski ST; Bouchardy C; Hirvonen A; Dayer P; Husgafvel-Pursiainen K
Eur J Cancer; 2000 Sep; 36(14):1825-32. PubMed ID: 10974631
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County.
London SJ; Daly AK; Leathart JB; Navidi WC; Carpenter CC; Idle JR
Carcinogenesis; 1997 Jun; 18(6):1203-14. PubMed ID: 9214604
[TBL] [Abstract][Full Text] [Related]
3. CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population.
Sobti RC; Sharma S; Joshi A; Jindal SK; Janmeja A
Biomarkers; 2003; 8(5):415-28. PubMed ID: 14602525
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism of CYP2D6 and lung cancer risk.
Shaw GL; Falk RT; Frame JN; Weiffenbach B; Nesbitt JC; Pass HI; Caporaso NE; Moir DT; Tucker MA
Cancer Epidemiol Biomarkers Prev; 1998 Mar; 7(3):215-9. PubMed ID: 9521436
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour.
Saarikoski ST; Sata F; Husgafvel-Pursiainen K; Rautalahti M; Haukka J; Impivaara O; Järvisalo J; Vainio H; Hirvonen A
Pharmacogenetics; 2000 Feb; 10(1):5-10. PubMed ID: 10739167
[TBL] [Abstract][Full Text] [Related]
6. GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking.
Schneider J; Bernges U; Philipp M; Woitowitz HJ
Cancer Lett; 2004 May; 208(1):65-74. PubMed ID: 15105047
[TBL] [Abstract][Full Text] [Related]
7. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
8. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
Christensen PM; Gøtzsche PC; Brøsen K
Eur J Clin Pharmacol; 1997; 51(5):389-93. PubMed ID: 9049580
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 genotype and the incidence of anal and vulvar cancer.
Chen C; Cook LS; Li XY; Hallagan S; Madeleine MM; Daling JR; Weiss NS
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):317-21. PubMed ID: 10207635
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians.
Legrand-Andréoletti M; Stücker I; Marez D; Galais P; Cosme J; Sabbagh N; Spire C; Cenée S; Lafitte JJ; Beaune P; Broly F
Pharmacogenetics; 1998 Feb; 8(1):7-14. PubMed ID: 9511176
[TBL] [Abstract][Full Text] [Related]
11. Association of Genetic Variants of CYP2C19 and CYP2D6 with Esophageal Squamous Cell Carcinoma Risk in Northern India, Kashmir.
Bhat GA; Bhat AB; Lone MM; Dar NA
Nutr Cancer; 2017; 69(4):585-592. PubMed ID: 28368717
[TBL] [Abstract][Full Text] [Related]
12. Risk of renal cell carcinoma and polymorphism in phase I xenobiotic metabolizing CYP1A1 and CYP2D6 enzymes.
Ahmad ST; Arjumand W; Seth A; Nafees S; Rashid S; Ali N; Hamiza OO; Sultana S
Urol Oncol; 2013 Oct; 31(7):1350-7. PubMed ID: 22281432
[TBL] [Abstract][Full Text] [Related]
13. [CYP2D6*10 polymorphisms and lung cancer susceptibility].
Yan Z; Wu YM; Wu YJ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Oct; 30(5):564-8. PubMed ID: 19024387
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers.
Matthias C; Bockmühl U; Jahnke V; Jones PW; Hayes JD; Alldersea J; Gilford J; Bailey L; Bath J; Worrall SF; Hand P; Fryer AA; Strange RC
Pharmacogenetics; 1998 Apr; 8(2):91-100. PubMed ID: 10022746
[TBL] [Abstract][Full Text] [Related]
15. Combined genetic polymorphism and risk for development of lung cancer.
el-Zein R; Zwischenberger JB; Wood TG; Abdel-Rahman SZ; Brekelbaum C; Au WW
Mutat Res; 1997 Nov; 381(2):189-200. PubMed ID: 9434875
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer.
Lemos MC; Carrilho F; Rodrigues F; Coutinho E; Gomes L; Carvalheiro M; Regateiro FJ
Clin Endocrinol (Oxf); 2007 Aug; 67(2):180-3. PubMed ID: 17547692
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2D6 activity and tobacco on larynx cancer risk.
Benhamou S; Bouchardy C; Paoletti C; Dayer P
Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):683-6. PubMed ID: 8877058
[TBL] [Abstract][Full Text] [Related]
18. [CYP2D6 and GSTM1 genetic polymorphism and lung cancer susceptibility].
Gao J; Ren C; Zhang Q
Zhonghua Zhong Liu Za Zhi; 1998 May; 20(3):185-6. PubMed ID: 10921002
[TBL] [Abstract][Full Text] [Related]
19. CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China.
Song N; Tan W; Xing D; Lin D
Carcinogenesis; 2001 Jan; 22(1):11-6. PubMed ID: 11159735
[TBL] [Abstract][Full Text] [Related]
20. Nicotine metabolism and CYP2D6 phenotype in smokers.
Caporaso NE; Lerman C; Audrain J; Boyd NR; Main D; Issaq HJ; Utermahlan B; Falk RT; Shields P
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):261-3. PubMed ID: 11303596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
